AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02948101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CSF1 Monoclonal Antibody PD-0360324
Description: Given IV
Study NCT02948101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT02948101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03034668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CS16-003 Full dose
Description: 350 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts
Study NCT03034668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CS16-003 Half dose
Description: 175 mg 'Rhodiola rosea L. \& Rhaptonticum carthamoides extracts + maltodextrin 175 mg
Study NCT03034668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin: 350 mg
Study NCT04508387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group HH (heated-humidified)
Description: Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
Study NCT00862251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (+) simvastatin
Description: ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
Study NCT00862251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 40 mg or atorvastatin 20 mg
Description: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
Study NCT00862251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: rosuvastatin 10 mg tablets, taken once daily for six weeks.
Study NCT00862251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 10 mg or simvastatin 20 mg
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
Study NCT00862251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin 10 mg or simvastatin 20 mg
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
Study NCT04609696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 1
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study NCT02547727 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
Study NCT01555086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited pelvic Lymphadenectomy
Description: approximately 10-14 lymph nodes are removed
Study NCT01555086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended pelvic Lymphadenectomy
Description: approximately 20 lymph nodes are removed
Study NCT00066001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metronidazole
Description: antibiotic that is particularly effective against Gram negative bacterial species
Study NCT00539110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolipidem
Description: zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
Study NCT04609696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Powder-In-Capsule 2
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study NCT02241096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
Study NCT03744000 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
Study NCT03744000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred stenting
Description: Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
Study NCT01070147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Asthma Management System
Description: The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
Study NCT03472443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
Study NCT03621345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
Study NCT03621345 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham block
Description: A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
Study NCT00056498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 16 weeks
Study NCT00056498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal
Description: Risperdal 4 mg per day for 16 weeks
Study NCT00539110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
Study NCT01683474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus MedTech Aortic Valve Prosthesis
Description: Percutaneous implantation of aortic valve of Venus-A
Study NCT01817985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5816
Study NCT02547727 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
Study NCT02132494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT04609696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan: Tablet
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Study NCT02613754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: See arm description.
Study NCT02613754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: See arm description
Study NCT02613754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: See arm description
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon-alpha (PegIFNα-2a)
Description: PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha (PegIFNα-2a)
Description: PegIFNα-2a (180 micrograms \[μg\] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
Study NCT01725529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken orally with food once-daily for 48 weeks.
Study NCT02082392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Study NCT02082392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance or treatment of no intended therapeutic value in a pill form.
Study NCT05119946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide prevention video
Description: The video has been developed by the research team as an educational tool to teach patients about suicide, the consequences of such and imparting a message of hope.
Study NCT05119946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard suicide treatment
Description: The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
Study NCT05119946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard suicide treatment
Description: The standard suicide treatment will be determine by the attending physician and can include medications and/or psychotherapy
Study NCT00207090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
Study NCT00207090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
Study NCT00833586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine HCl 250mg tablets
Description: 1 x 250 mg
Study NCT00833586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® 250 mg Tablets
Description: 1 x 250 mg
Study NCT06510634 — intervention group
Intervention type: OTHER
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.
Study NCT03380845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore
Description: Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
Study NCT03380845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractora
Description: Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
Study NCT01043952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Study NCT01043952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Study NCT01043952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Study NCT01043952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Study NCT01043952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index Monitor
Description: Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
Study NCT01575457 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Career Counseling and Motivational Interviewing
Description: The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
Study NCT01575457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Career Counseling and Motivational Interviewing
Description: The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
Study NCT03857581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
Study NCT02405481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEPA III
Study NCT03148847 — intervention group
Intervention type: OTHER
Intervention: Baseline care
Study NCT01389245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX
Description: OsseoSpeed™ TX implants of lengths 8-17 mm
Study NCT05225155 — intervention group
Intervention type: DRUG
Intervention: Enoxaparin
Description: Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
Study NCT00559091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
Study NCT03424226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
Study NCT03424226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
Study NCT01851967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoodGYM
Description: MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
Study NCT04390685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
Study NCT02038322 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: The Stork - Conception Aid
Study NCT02339948 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
Study NCT04340050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 convalescent plasma
Description: Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
Study NCT06165588 — intervention group
Intervention type: OTHER
Intervention: Tour de France
Description: Participating in the Tour de France as cyclist
Study NCT02406755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one-sensory self care (Todo Dia®)
Description: daily use of odorless body moisturizer (Todo Dia® - Natura)
Study NCT02406755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multisensory self care (Todo Dia®)
Description: daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
Study NCT02406755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bi-sensory self care (Todo Dia®)
Description: daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02241863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
Study NCT02241863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine counseling
Study NCT01701492 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
Study NCT01701492 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Evaluation
Description: A one-time neurocognitive evaluation conducted in the Psychology Clinic